The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Biolinerx’s BL-8040 needs to show improved responses in pancreatic cancer while investors will get a first look at Homology's HMI-102, a gene therapy for…
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…